首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1735610

2026 年至 2032 年季節性流感疫苗市場（按類型、疫苗類型、疫苗效力、年齡層、分銷管道和地區分類）

Seasonal Influenza Vaccine Market By Type, Vaccine Type, Valency Route of Administration Age Group, Distribution Channel, & Region for 2026-2032.

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年季節性流感疫苗市場評估

隨著全球報告的流感病例不斷增加，預計流感疫苗需求也將增加，刺激市場擴張。預計未來幾年，全球流感疫苗市場將迅速擴張。這得益於老年人口的成長、人們意識的提高、政府疫苗宣傳活動以及流感爆發頻率的增加。預計2024年季節性流感疫苗市值約為79.7億美元，到2032年將達到165.9億美元。

市場參與企業和政府之間加強合作，在偏遠地區提供流感疫苗（如豬流感疫苗），預計將加速市場成長，這將有助於市場在 2026 年至 2032 年期間以 8.2% 的複合年成長率成長。

季節性流感疫苗市場定義/概述

流感疫苗，又稱為流感疫苗接種，可預防影響呼吸系統的感染疾病，並引起頭痛、疲倦、流鼻水、發燒、肌肉疼痛和鼻塞等症狀。流感是感染疾病，感染者咳嗽或打噴嚏時會迅速傳播，並可能導致輕度至重度疾病。

季節性流感是由流感病毒引起的一種反覆發作的呼吸道疾病，與其診斷、治療和預防相關的經濟活動被稱為季節性流感市場。

在目前的市場環境下，世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）等政府機構已研發出多種已獲許可的季節性流感疫苗。此外，WHO也啟動了全球流感規劃（GISRS）等活動，以監測全球流感活動。

此外，流感疫苗市場的擴張得益於政府措施推動的常規疫苗接種計畫的增加，以及已開發國家和新興經濟體都將流感疫苗接種納入其中。全球流感疫苗市場研究對該行業進行了全面的分析。

季節性流感疫苗特異性感染預防的主要變數是什麼？

據世界衛生組織稱，世界人口的成長、季節性流感疫苗

已接種許可疫苗的族群併發症的風險增加，包括孕婦、6 至 59 個月大的兒童、老年人和醫護人員。

預防流感最有效的方法是接種已使用超過60年的可靠疫苗。由於流感病毒不斷進化和變化，建議每年接種疫苗以保護自己免受流感侵害。

人們對流感和疫苗接種計畫的認知不斷提高，疫苗接種覆蓋率也隨之提高，市場也隨之提高。流感相關疾病負擔的日益加重，加上嚴重疫情和大流行的可能性，正在刺激對季節性流感疫苗作為預防措施的需求。

疫苗技術的進步，例如細胞和重組方法，提高了這些疫苗的效率、安全性和有效性。世界衛生組織（WHO）和美國疾病管制與預防中心等國際組織提倡將季節性流感疫苗接種作為預防策略，以減少疾病傳播並保護弱勢群體。

全球疫苗接種舉措，包括中低收入國家的疫苗宣傳活動，正在透過擴大全球流感疫苗的可及性來促進市場成長。醫療保健提供者和醫療機構的需求，加上年度疫苗接種建議，正在推動市場成長，因為越來越多的人在流感季節尋求疫苗接種服務。 COVID-19 疫情凸顯了針對流感等呼吸道病毒的有效疫苗接種策略的重要性，促使各國政府、醫療機構和製藥公司將流感疫苗的研發和分發列為優先事項。

大型醫療保健公司正在投入大量精力和資金，用於疫苗研發，將其作為尖端治療方法。例如，2021年8月，Sequirus投資了一種名為「自擴增mRNA」的未來流感疫苗技術。

季節性流感疫苗有哪些副作用？

隨著研發不斷提高耐用性、有效性並解決副作用問題，對流感疫苗的需求持續成長，同時確保當地的可用性和可負擔性對於實現市場潛力至關重要。

任何疫苗都存在副作用，會以各種方式影響身體，例如皮疹、發燒、疼痛、發冷等，這限制了市場的成長。農村缺乏相關教育和經驗，導致兒童未能接種疫苗，增加了幼年感染病毒性流感的風險。大眾對疫苗接種的認知和信任度受到負面宣傳的影響，這可能會阻礙市場的成長。

接種季節性流感疫苗的好處大於風險。市場可以透過克服這一限制、巧妙地應對擔憂並促進疫苗安全來確保流感疫苗的更廣泛使用。疫苗有其局限性，因為流感病毒會降低疫苗對季節性流行病毒株的有效性。

根據美國國家醫學圖書館報道，新冠疫苗與季節性流感疫苗相比，兩種疫苗的嚴重率和死亡率都有限，季節性流感疫苗的轉變速度比新冠疫苗更快。

The demand for influenza vaccines is expected to increase in response to the rising number of influenza cases reported globally, fueling the market's expansion. The market for influenza vaccines is anticipated to expand quickly on a global scale over the next years. This can be attributed to the growth in elderly population, awareness, and government vaccination campaigns, as well as a rise in frequency of the flu. The seasonal influenza vaccine market was valued at around USD 7.97 Billion in 2024 and projected to reach USD 16.59 Billion valued in 2032.

It is anticipated that an increase in collaborations between industry participants and governments to guarantee the availability of flu shots, like the swine flu vaccine, in isolated regions will quicken market growth. It enables the market to grow at a CAGR of 8.2% from 2026-2032.

Seasonal Influenza Vaccine Market: Definition/ Overview

Influenza Vaccine is also known as flu shots. This vaccines protect against infection. It affects the respiratory system and causes symptoms such as headaches, lethargy, runny nose, fever, muscular aches, and congestion. Infection that spreads quickly through an infected person's cough and sneezes and can cause mild to severe illness.

The economic activity related to the diagnosis, treatment, and prevention of seasonal influenza, a recurrent respiratory ailment brought on by influenza viruses, is referred to as the seasonal influenza market.

The disease in the current market environment, the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other governmental agencies prescribe a number of licensed seasonal influenza vaccines. Moreover, the WHO has started the Global Influenza Program and GISRS, which work along with other organizations to monitor influenza activity worldwide.

Furthermore, increase of the influenza vaccine market is attributed to the growth of routine vaccination programs with government initiatives and inclusion of influenza vaccinations in these programs in both developed and developing nations. The study on the global influenza vaccine market offers a comprehensive analysis of the industry.

What are the Key Variables Factors for Seasonal Influenza Vaccines to Protect Agent Influence Disease?

The increasing population globally according to WHO, sessional influenza vaccines are

elevated risk complications to the group of pregnant women, children at the age of 6-59 months, old peoples, are getting licensed vaccines available including healthcare workers.

Most effective way to protect agent influenza disease by using reliable immunizations that have been in use for more than 60 years. An annual vaccination is advised to guard against influenza as the virus is ever-evolving and changing to protect it eroding.

The increasing awareness and vaccination programs about influenza is leading to higher vaccination rates and market growth. The growing burden of influenza-related illness, coupled with the potential for severe outbreaks or pandemics, has fueled demand for seasonal influenza vaccines as a preventive measure.

Advancements in vaccine technology, such as cell-based and recombinant methods, have improved the efficiency, safety, and effectiveness of these vaccines. International organizations like the World Health Organization and Centers for Disease Control and Prevention advocate for seasonal influenza vaccination as a preventive strategy to reduce disease transmission and protect vulnerable populations.

Global immunization initiatives, including vaccination campaigns in low- and middle-income countries, contribute to market growth by expanding access to influenza vaccines worldwide. Demand from healthcare providers and institutions, coupled with recommendations for annual vaccination, drives market growth as more individuals seek vaccination services during the influenza season. The COVID-19 pandemic has highlighted the importance of effective vaccination strategies against respiratory viruses like influenza, with governments, healthcare agencies, and pharmaceutical companies prioritizing research, development, and distribution of influenza vaccines.

Major healthcare companies are investing a great deal of effort and money into developing vaccines as cutting-edge treatments. As an illustration, in August 2021, Seqirus invested in the future influenza vaccine technology of self-amplifying mRNA.

What are the Side Effects of the Seasonal Influenza Vaccines?

The demand for influenza vaccines ongoing in research and development to enhance durability, efficacy, and address adverse effect issues. In additionally realizing the market potential is essential to provide accessibility and affordability across every region.

Any vaccines contain a number of side effects that can affect the body in many ways, including rashes, fever, pain, soreness, chills, and many more that limit the market's ability to grow. In rural areas there is a shortage of education and experience. Due to that children's are not vaccinated increasing the risk of contracting the viral flu from an early age. Public awareness or the trust about the vaccination can hinder the market growth because of negative publicity surrounding.

The advantages of getting vaccinated against seasonal influenza outweigh the dangers. The market may overcome this constraint and guarantee broader influenza vaccine use by skillfully resolving concerns and promoting vaccine safety. The virus reduce the vaccine effectiveness to the prevalent strain predicated for every season, which makes limitation of vaccines.

According to the National Library of Medicine, comparing the COVID-19 vaccine and seasonal influenza vaccine they may contain limited fraction of critical cases or morality rate. The seasonal influenza vaccine can transfer faster than the COVID-19.

Category-Wise Acumens

What Kind of Effectiveness Offered by Inactive Product to Contribute to Leading Position in Seasonal Influenza Vaccines Market?

As industry estimates the inactivated category will control the majority of the market in 2023. Industrialists' increasing focus on vaccines is driving a demand for inactivated vaccines in both developed and developing nations, as they are standardized based on specific virus strains. The greatest CAGR of the category over the projection period is primarily owing to the rising demand and high influenza prevalence.

There are ample evidence of their efficacy. Inactive Influenza Vaccines (IIVs) have a lengthy history building market demand, developing confidence, and offering significant protection against seasonal influenza viruses. When the circulating strains of the virus match the vaccination, they induce developed protection by targeting specific influenza antigens.

The safety profile of IIVs is very good. They are suitable for a wide spectrum of people and have moderate, transient negative effects.

Live attenuated category is expected to expand more slowly because of the many obstacles that companies must overcome to develop and approve vaccines. Furthermore, certain patients such as those with weak immune systems, asthma, and pregnant women should not receive the live attenuated vaccination.

How the Adoption of Seasonal Influenza Vaccines is Increasing in the Adults?

The majority of the market for seasonal influenza vaccinations is occupied by adults. Individuals with pre-existing medical disorders are more susceptible to serious influenza-related consequences, such as hospitalization and maybe fatality. The need for adult vaccinations is fueled by the necessity of vaccination for their protection. This is further supported by public health recommendations, which strongly advise high-risk persons to have an annual influenza vaccination.

The adult age group held a major share of the worldwide influenza vaccine market in terms of market share in 2022. There are significantly more adults than children in the population. The World Population Review of 2020 estimates that there were around 46 Billion adults over the age of 18, and approximately 1.2 Billion children between the ages of 12 and 18.

Furthermore, fewer influenza vaccinations are available for children than for adults. For example, the first COVID-19 vaccine approved in the United States was the Pfizer-BioNTech vaccine, and it was only approved for use in adults 16 years of age and older. As a result, adults are more likely than younger people to receive vaccinations.

Country/Region-wise Acumens

Does North America Hold Highest Market Share in the Seasonal Influenza Vaccines Market?

During, the projected period North America is anticipated to hold the highest market share. This has been brought to increased public awareness of influenza infections and the treatments that are available, government education initiatives and the development of new vaccines made possible by technological developments.

The existence of significant market players in the area and their substantial R&D spending are further factors contributing to the industry's growth. The influenza pandemic has become more often in North America, boosting the growth of seasonal influenza vaccine market.

The biggest markets for seasonal influenza vaccinations is North America. The high rate of flu in the area and the well-established healthcare system are the main drivers of the market. Children's at the age of six months and older should get the flu shot every year, according to the Centers for Disease Control and Prevention (CDC). The influenza vaccine market in North America is also being driven by a rise in awareness of the value of vaccination.

How will Seasonal Influenza Vaccine Market Fare in Asia Pacific?

The Asia Pacific area is turning into the global influenza vaccine market with the fastest rate of growth. Some of the main reasons propelling market expansion are governments' increased attention on immunization programs, growing per capita healthcare expenditures, and expanding healthcare infrastructure.

Whereas China, India, and Japan are leading the way in public health awareness campaigns because of their sizable populations and public health organizations' activities. Asia has experienced in sales of vaccines as a result of changing lifestyles and an increase in influenza-related diseases in recent years.

It is expected that Asia Pacific would have a higher CAGR over the projection period. The region's market is expected to develop as a result of the growing number of government activities to distribute these vaccines and raise awareness about influenza.

Competitive Landscape

The competitive landscape of the seasonal influenza vaccine market is characterized by several key players and factors that influence market dynamics, innovation, and strategic initiatives. These players completely based on Product portfolio, business segment, business strategies and recent development.

Some of the prominent players operating in the seasonal influenza vaccine market include:

Sanofi
Merck & Co
Novartis
GlaxoSmithKline
Changsheng
Bio-Technology Co., Ltd.
OSIVAX
Abbott Laboratories
Aleph Biomedical.
AstraZeneca
SINOVAC
Vietris Inc.
BIKEN Co., Ltd
GSK plc
Pfizer Inc.
Vaxess Technologies Inc.
EMERGEX VACCINES

Latest Developments

In October 2023, the outcomes of Moderna Inc.'s m-RNA-based vaccination for COVID-19 and influenza were revealed.
In May 2023, GSK and CureVac launched the phase Ill influenza study for GSK's mRNA-based vaccination.
In September 2022, Pfizer Inc. declared that the company's quadrivalent modified RNA influenza vaccine candidate has reached the first dose of participants in a pivotal phase 3 clinical study to assess the vaccine's immunogenicity, safety, tolerability, and efficacy.
In February 2021, Pfizer and BioNTech declared that the COVID-19 vaccine was approved for use in emergency situations in the United States. This approval represented a significant turning point in the global fight against COVID-19 and showed that pharmaceutical companies can quickly create and commercialize vaccines to prevent the spread of infectious illnesses.

1 INTRODUCTION OF GLOBAL SEASONAL INFLUENZA VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL SEASONAL INFLUENZA VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY TYPE

5.1 Overview
5.2 Inactivated
5.3 Live Attenuated

6 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY VACCINE TYPE

6.1 Overview
6.2 Quadrivalent
6.3 Trivalent

7 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY VALENCY

7.1 Overview
7.1 Quadrivalent
7.1 Trivalent

8 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION

8.1 Overview
8.1 Injection
8.1 Nasal Spray

9 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY AGE GROUP

9.1 Overview
9.1 Pediatric
9.1 Adults

10 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY DISTRIBUTION CHANNEL

10.1 Overview
10.1 Hospital & Retail Pharmacies
10.1 Government & Institutional Supply

11 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY

11.1 Overview
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.2.3 Mexico
11.3 Europe
- 11.3.1 Germany
- 11.3.2 U.K.
- 11.3.3 France
- 11.3.4 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Rest of Asia Pacific
11.5 Rest of the World
- 11.5.1 Latin America
- 11.5.2 Middle East and Africa

12 GLOBAL SEASONAL INFLUENZA VACCINE MARKET COMPETITIVE LANDSCAPE

12.1 Overview
12.2 Company Market Ranking
12.3 Key Development Strategies

13 COMPANY PROFILES

13.1 Sanofi
- 13.1.1 Overview
- 13.1.2 Financial Performance
- 13.1.3 Product Outlook
- 13.1.4 Key Developments
13.2 Merck & Co
- 13.2.1 Overview
- 13.2.2 Financial Performance
- 13.2.3 Product Outlook
- 13.2.4 Key Developments
13.3 Novartis
- 13.3.1 Overview
- 13.3.2 Financial Performance
- 13.3.3 Product Outlook
- 13.3.4 Key Developments
13.4 GlaxoSmithKline
- 13.4.1 Overview
- 13.4.2 Financial Performance
- 13.4.3 Product Outlook
- 13.4.4 Key Developments
13.5 Changsheng Bio-Technology Co., Ltd.
- 13.5.1 Overview
- 13.5.2 Financial Performance
- 13.5.3 Product Outlook
- 13.5.4 Key Developments
13.6 Abbott Laboratories
- 13.6.1 Overview
- 13.6.2 Financial Performance
- 13.6.3 Product Outlook
- 13.6.4 Key Developments
13.7 Aleph Biomedical
- 13.7.1 Overview
- 13.7.2 Financial Performance
- 13.7.3 Product Outlook
- 13.7.4 Key Developments